PCSK9 Forum
Click here to forward this email to a colleague
Facebook Twitter RSS YouTube linkedin
Home  |  About  |  PCSK9  |  News  |  Commentary  |  Trials  |  Videos  |  Resources  |  Contact

News from the European Society of Cardiology Congress,
25-29 August, Munich, Germany

More insights from the FOURIER Trial

Greater clinical benefit from evolocumab in patients with metabolic syndrome, with no evidence for an increase in new-onset diabetes mellitus.

Read the report »

Lowering LDL cholesterol with evolocumab confers similar benefit in men and women and across a wide range of ages.

Read the report »

More real-world experience with the use of PCSK9 inhibitors

Accumulating data vindicate the European Society of Cardiology/European Atherosclerosis Society Task Force practical guidance for the use of PCSK9 inhibitors.

Read the report »

Catch-up on the Task Force guidance: Lead author Professor Ulf Landmesser, Charité – Universitätsmedizin Berlin, Germany discusses the guidance in the light of results from FOURIER and ODYSSEY Outcomes.

Watch the video »

Like us on Facebook
For the latest updates, PCSK9 news and analysis.
Follow us on Twitter
Hot topics, news and conference reports.
YouTube Channel
For videos, interviews and webcasts from leading experts.
Our popular therapeutic guide

Read online & download second edition now »

Register now at www.pcsk9forum.org to receive the updated third edition coming soon.
New eBook
Questions & Answers

Why are new treatments needed?

Read the full answer and other questions on the PCSK9 Forum »
Educational Partners
and Supporters
Amgen The Medicines Company Sanofi
Copyright PCSK9 Forum 2018. Please click here to unsubscribe from future mailings.